The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Agreed, if revenues are ahead of last year, and margins are maintained, then this has to double. It's a complete head scratcher as to why this is so cheap. I think there's a lot of confusion about the reporting (group earnings vs company) and how the NCI payments work, so if they can clear this up in December this should be a multibagger
I’m sure this will bag at least, after December results.
I think that must be the reason Beza as the trading update didn't read too badly to me, but this is a share that continually baffles me so what do I know!
Despite the frustration this share has caused me since buying earlier this year, this share is still criminally undervalued and I will continue to hold awaiting a) a rerate and b) a dividend reinstatement, both of which will come
Guess so
they have reduced the dept by over a million in 4 months aswell as revenue above last year for first 5 months an huge savings.
Inpatient greedy traders looking for quick cash imo
Why has the market took over 10% off these? Is because they were hoping to hear that the divi is being reinstated?
Trading update statement
Trading since 1 April 2020
› Revenue for 5 months to 31 August 2020 ahead of last year
› All overseas offices revenues ahead of last year with improving gross margin and contributing to the Group
› Covid-19 has limited UK revenues, particularly in aviation, real estate and corporate sectors but shipping and dispute resolution have more stable levels of activity
› Reduction of overheads and other expenditure continues including modest redundancy programme in the wake of Covid-19
› Further operational efficiencies yet to be achieved from rolling out new practice management system beyond the UK
› Net debt position improved since 31 March although collections continue to be slow particularly in Greater China
› On track to achieve board’s expectations at the time the accounts were signed
› Well positioned for when normal trading conditions resume